Pharma BD Deal Intelligence
On 2026-10-05 CSL and Alentis Therapeutics entered an exclusive global collaboration to co-develop and co-promote lixudebart, a potential first-in-class anti-claudin-1 monoclonal antibody, in rare kidney and liver disease. Alentis receives USD 355M upfront and is eligible for up to USD 1.2B in milestones, with profits split 55% to CSL and 45% to Alentis. The lead indication is ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), with additional development planned in focal segmental glomerulosclerosis and primary sclerosing cholangitis. CSL fully funds completion of the ongoing Phase 2 RENAL trial and the planned Phase 3 trial in AAV-RPGN as well as the Phase 2 FSGS and PSC trials. Reported early data showed improved kidney function at 24 weeks in AAV-RPGN patients and improved liver function at 6 weeks in patients with advanced liver fibrosis.
← Browse all deals · How we score deals
More: 2026 deals · CSL Limited deals